Inactive Instrument

Cancer Genetics, Inc.

Equities

CGIX

US13739U2033

Cancer Genetics, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020

November 12, 2020 at 04:22 pm EST

Cancer Genetics, Inc. announced earnings results for the third quarter ended September 30, 2020. For the third quarter, the company announced sales was USD 1.568 million compared to USD 2.069 million a year ago. Operating loss was USD 1.369 million compared to USD 3.642 million a year ago. Net loss was USD 1.353 million compared to net income of USD 1.975 million a year ago. Basic loss per share was USD 0.58 compared to basic earnings per share of USD 0.98 a year ago. Basic loss per share from continuing operations was USD 0.58 compared to USD 2.38 a year ago. For the nine months, sales was USD 4.440 million compared to USD 5.416 million a year ago. Operating loss was USD 4.341 million compared to USD 5.499 million a year ago. Net loss was USD 4.232 million compared to USD 6.415 million a year ago. Basic loss per share was USD 1.93 compared to USD 3.47 a year ago. Basic loss per share from continuing operations was USD 1.96 compared to USD 3.77 a year ago.

Latest news about Cancer Genetics, Inc.

Cancer Genetics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-16	CI
Cancer Genetics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-30	CI
Cancer Genetics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	21-03-31	CI
Cancer Genetics, Inc. has Changed its Ticker to VYNT from CGIX	21-03-31	CI
Cancer Genetics, Inc. has Changed its Name to Vyant Bio, Inc	21-03-30	CI
Cancer Genetics, Inc.(NasdaqCM:CGIX) dropped from NASDAQ Composite Index	21-03-30	CI
StemoniX Inc. completed the acquisition of Cancer Genetics, Inc. from a group of shareholders in a reverse merger transaction.	21-03-29	CI
Cancer Genetics : Secures Shareholder Nod for Proposed StemoniX Merger	21-03-25	MT
Cancer Genetics, Inc. Appoints Roland J. Carrillo as the Vice President of Business Development	21-03-18	CI
Cancer Genetics : to Raise $17.5 Million in Common Stock Offering	21-02-11	MT
Cancer Genetics, Inc. announced that it has received $10.000012 million in funding	21-01-31	CI
Cancer Genetics, Inc. announced that it expects to receive $10.000012 million in funding	21-01-27	CI
Certain Common Stock of Cancer Genetics, Inc. are subject to a Lock-Up Agreement Ending on 27-JAN-2021.	21-01-26	CI
Certain Stock Option of Cancer Genetics, Inc. are subject to a Lock-Up Agreement Ending on 27-JAN-2021.	21-01-26	CI
Certain Warrants of Cancer Genetics, Inc. are subject to a Lock-Up Agreement Ending on 27-JAN-2021.	21-01-26	CI
Cancer Genetics, Inc. Announces Executive Changes	20-11-20	CI
Cancer Genetics : Earnings Flash (CGIX) CANCER GENETICS Reports Q3 Revenue $1.57M	20-11-12	MT
Cancer Genetics : Earnings Flash (CGIX) CANCER GENETICS Reports Q3 Revenue $1.57M	20-11-12	MT
Cancer Genetics, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-11-12	CI
Cancer Genetics, Inc. Announces Departure of Glenn Miles as Chief Financial Officer, Effective November 16, 2020	20-10-19	CI
Cancer Genetics, Inc. Announces Resignation of Dr. Raju S.K. Chaganti	20-09-30	CI
Cancer Genetics, Inc. and StemoniX Inc. Announce Joint Proof of Concept Program	20-09-03	CI
StemoniX Inc. entered into a definitive merger agreement to acquire Cancer Genetics, Inc. from a group of shareholders for $55.1 million in a reverse merger transaction.	20-08-23	CI
Cancer Genetics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020	20-08-13	CI
Cancer Genetics Mulls Strategic Options	20-06-01	CI

Chart Cancer Genetics, Inc.

Duration

Period

More charts

Company Profile

Cancer Genetics, Inc. is engaged in the field of personalized medicine, enabling precision medicine in the field of oncology through its diagnostic products and services and molecular markers. Through its subsidiary, the Company offers preclinical test systems. The Company offers discovery services to the pharmaceutical industry, biotechnology companies and academic research centers. The Company provides the tools and testing methods for companies and researchers to identify new molecular- and biomarker-based indicators for disease and to determine the pharmacogenomics, toxicity and efficacy of therapeutic candidate compounds. Its discovery services include development of both xenograft and syngeneic animal models, toxicology and genetic toxicology services, pharmacology testing, pathology services, and validation of biomarkers for diseases including cancers. It also provides consulting, guidance and preparation of samples.

Sector

More about the company